<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xml:lang="en" article-type="research-article" xmlns:xlink="http://www.w3.org/1999/xlink">
<?release-delay 0|0?>
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">OL</journal-id>
<journal-title-group>
<journal-title>Oncology Letters</journal-title>
</journal-title-group>
<issn pub-type="ppub">1792-1074</issn>
<issn pub-type="epub">1792-1082</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3892/ol.2016.5340</article-id>
<article-id pub-id-type="publisher-id">OL-0-0-5340</article-id>
<article-categories>
<subj-group>
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>MicroRNA-320 regulates the radiosensitivity of cervical cancer cells C33AR by targeting &#x03B2;-catenin</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author"><name><surname>Yang</surname><given-names>Chun-Xu</given-names></name>
<xref rid="af1-ol-0-0-5340" ref-type="aff">1</xref>
<xref rid="fn1-ol-0-0-5340" ref-type="author-notes">&#x002A;</xref></contrib>
<contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Shi-Min</given-names></name>
<xref rid="af1-ol-0-0-5340" ref-type="aff">1</xref>
<xref rid="fn1-ol-0-0-5340" ref-type="author-notes">&#x002A;</xref></contrib>
<contrib contrib-type="author"><name><surname>Li</surname><given-names>Jie</given-names></name>
<xref rid="af1-ol-0-0-5340" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author"><name><surname>Yang</surname><given-names>Bo</given-names></name>
<xref rid="af1-ol-0-0-5340" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author"><name><surname>Ouyang</surname><given-names>Wen</given-names></name>
<xref rid="af1-ol-0-0-5340" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author"><name><surname>Mei</surname><given-names>Zi-Jie</given-names></name>
<xref rid="af1-ol-0-0-5340" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author"><name><surname>Chen</surname><given-names>Jing</given-names></name>
<xref rid="af1-ol-0-0-5340" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author"><name><surname>Dai</surname><given-names>Jing</given-names></name>
<xref rid="af1-ol-0-0-5340" ref-type="aff">1</xref>
<xref rid="af2-ol-0-0-5340" ref-type="aff">2</xref></contrib>
<contrib contrib-type="author"><name><surname>Ke</surname><given-names>Su</given-names></name>
<xref rid="af1-ol-0-0-5340" ref-type="aff">1</xref>
<xref rid="af3-ol-0-0-5340" ref-type="aff">3</xref></contrib>
<contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Fu-Xiang</given-names></name>
<xref rid="af1-ol-0-0-5340" ref-type="aff">1</xref>
<xref rid="af2-ol-0-0-5340" ref-type="aff">2</xref></contrib>
<contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Yun-Feng</given-names></name>
<xref rid="af1-ol-0-0-5340" ref-type="aff">1</xref>
<xref rid="af2-ol-0-0-5340" ref-type="aff">2</xref></contrib>
<contrib contrib-type="author"><name><surname>Xie</surname><given-names>Cong-Hua</given-names></name>
<xref rid="af1-ol-0-0-5340" ref-type="aff">1</xref>
<xref rid="af2-ol-0-0-5340" ref-type="aff">2</xref>
<xref rid="c1-ol-0-0-5340" ref-type="corresp"/></contrib>
</contrib-group>
<aff id="af1-ol-0-0-5340"><label>1</label>Department of Radiation and Medical Oncology, Zhongnan Hospital, Wuhan University, Wuhan, Hubei 430071, P.R. China</aff>
<aff id="af2-ol-0-0-5340"><label>2</label>Department of Radio-Chemotherapy, Wuhan University, Wuhan, Hubei 430071, P.R. China</aff>
<aff id="af3-ol-0-0-5340"><label>3</label>Department of Nephrology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China</aff>
<author-notes>
<corresp id="c1-ol-0-0-5340"><italic>Correspondence to</italic>: Professor Cong-Hua Xie, Department of Radiation and Medical Oncology, Zhongnan Hospital, Wuhan University, 169 Donghu Road, Wuchang, Wuhan, Hubei 430071, P.R. China, E-mail: <email>chxie_65@hotmail.com</email></corresp>
<fn id="fn1-ol-0-0-5340"><label>&#x002A;</label><p>Contributed equally</p></fn>
</author-notes>
<pub-date pub-type="ppub">
<month>12</month>
<year>2016</year></pub-date>
<pub-date pub-type="epub">
<day>02</day>
<month>11</month>
<year>2016</year></pub-date>
<volume>12</volume>
<issue>6</issue>
<fpage>4983</fpage>
<lpage>4990</lpage>
<history>
<date date-type="received"><day>19</day><month>05</month><year>2015</year></date>
<date date-type="accepted"><day>30</day><month>09</month><year>2016</year></date>
</history>
<permissions>
<copyright-statement>Copyright: &#x00A9; Yang et al.</copyright-statement>
<copyright-year>2016</copyright-year>
<license license-type="open-access">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivs License</ext-link>, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.</license-p></license>
</permissions>
<abstract>
<p>Cervical cancer is the second most common malignancy in women worldwide and always has recurrence owing to radioresistance. MicroRNA (miRNA or miR) has been identified to relate to the sensitivity of cancer radiotherapy. Here, we investigated the potential of miRNA-320 as a biomarker for radiosensitivity by targeting &#x03B2;-catenin in cervical cancer. A radioresistant cervical cancer cell line, C33AR, was established, and the radioresistance of C33AR cells was confirmed by a colony-formation assay. The expression of miRNA-320 was detected by reverse transcription-quantitative polymerase chain reaction, and compared between C33A and C33AR. &#x03B2;-catenin, the target of miRNA-320, was determined at the protein level by western blotting after transfecting the inhibitor of miRNA-320. The expression of miRNA-320 was markedly decreased in C33AR cells, which appeared to be more radioresistant, compared with its parental cell line C33A. Target prediction suggested that miRNA-320 negatively regulated the expression of &#x03B2;-catenin. Knockdown of &#x03B2;-catenin increased C33AR radiosensitivity, which revealed that the inhibition of &#x03B2;-catenin could rescue the miRNA-320-mediated cell radioresistance. On the other hand, overexpressing miRNA-320 increased C33AR radiosensitivity. In conclusion, miRNA-320 regulated the radiosensitivity of C33AR cells by targeting &#x03B2;-catenin. This finding provides evidence that miRNA-320 may be a potential biomarker of radiosensitivity in cervical cancer.</p>
</abstract>
<kwd-group>
<kwd>miRNA-320</kwd>
<kwd>&#x03B2;-catenin</kwd>
<kwd>C33AR</kwd>
<kwd>cervical cancer</kwd>
<kwd>radiosensitivity</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Cervical cancer, the second most common malignancy in women worldwide, is often diagnosed at a local and advanced stage (<xref rid="b1-ol-0-0-5340" ref-type="bibr">1</xref>). Radiotherapy is one of the most important treatments (<xref rid="b1-ol-0-0-5340" ref-type="bibr">1</xref>). However, radioresistance (inherent and acquired) often circumvents the efficacy of radiotherapy (<xref rid="b2-ol-0-0-5340" ref-type="bibr">2</xref>). Many patients have tumour recurrence due to radiotherapeutic resistance (<xref rid="b2-ol-0-0-5340" ref-type="bibr">2</xref>). However, the mechanisms of radioresistance are poorly understood.</p>
<p>MicroRNAs (miRNAs or miRs) are a class of non-coding RNAs, ~20-22-nucleotides long, which negatively regulate the expression of many cancer-related genes by binding to 3&#x2032;-untranslated regions (UTRs) (<xref rid="b3-ol-0-0-5340" ref-type="bibr">3</xref>&#x2013;<xref rid="b5-ol-0-0-5340" ref-type="bibr">5</xref>). Considerable evidence suggests that miRNAs are associated with multiple processes, including the tumorigenesis, proliferation and migration of many types of cancer (<xref rid="b6-ol-0-0-5340" ref-type="bibr">6</xref>&#x2013;<xref rid="b9-ol-0-0-5340" ref-type="bibr">9</xref>). For example, miRNA-610 downregulated vasodilator-stimulated phosphoprotein to influence the invasion and migration of gastric cancer cells (<xref rid="b10-ol-0-0-5340" ref-type="bibr">10</xref>), and miRNA-144 promoted cell proliferation, migration and invasion in nasopharyngeal carcinoma through repression of phosphatase and tensin homolog (<xref rid="b11-ol-0-0-5340" ref-type="bibr">11</xref>). Growing evidence suggests that some miRNAs are related to radioresistance, such as miRNA-31, miRNA-181, miRNA-324-3p and miRNA-214 (<xref rid="b12-ol-0-0-5340" ref-type="bibr">12</xref>&#x2013;<xref rid="b15-ol-0-0-5340" ref-type="bibr">15</xref>). However, the functions of miRNAs in radioresistance are still largely unknown. In this study, X-rays induced the expression of miRNA-320 in the radioresistant cervix cancer subline C33AR. Furthermore, target prediction suggested that miRNA-320 influences cervical cancer radiosensitivity by targeting &#x03B2;-catenin. The activation of &#x03B2;-catenin plays a crucial role in human cancers through the canonical Wnt/&#x03B2;-catenin signaling pathway, and the expression of &#x03B2;-catenin in cervical carcinoma causes a malignant phenotype (<xref rid="b16-ol-0-0-5340" ref-type="bibr">16</xref>). Our findings therefore suggest that a decrease in the expression of miRNA-320 promotes radioresistance in the C33AR cervical cancer cell line by permitting &#x03B2;-catenin expression.</p>
</sec>
<sec sec-type="materials|methods">
<title>Materials and methods</title>
<sec>
<title/>
<sec>
<title>Cell culture and transfection</title>
<p>The human cervical cell line C33A was obtained from the Shanghai Life Science Institute Cell Library (Shanghai, China). C33A and the acquired radioresistant cell line C33AR were cultured in Minimum Essential Medium (MEM) (HyClone; GE Healthcare Life Sciences, Logan, UT, USA) supplemented with 10&#x0025; fetal bovine serum (HyClone; GE Healthcare Life Sciences), penicillin-streptomycin liquid (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) and 0.25 &#x00B5;g/ml amphotericin B (Amresco, Inc., Framingham, MA, USA) in a humidified atmosphere of 5&#x0025; CO<sub>2</sub> at 37&#x00B0;C. The miRNA-320 agomir (a novel class of chemically engineered miRNA mimic) and negative control were purchased from Guangzhou RiboBio Co., Ltd. (Guangzhou, China). Cells were transfected with 100 nM miRNA-320 agomir or negative control using Lipofectamine 2000 in Opti-MEM (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer&#x0027;s instructions. A miRNA-320 inhibitor antiagomir (Guangzhou RiboBio Co., Ltd.) was designed to suppress the expression of miRNA-320. Small interference RNA (siRNA) was used to inhibit &#x03B2;-catenin expression. The siRNAs against &#x03B2;-catenin as well as the non-targeting control siRNAs were obtained from Shanghai GenePharma Co., Ltd. (Shanghai, China). Cells were transfected with siRNAs at a concentration of 25 nM using Lipofectamine 2000. The sequence of the &#x03B2;-catenin siRNA was 5&#x2032;-GGACACAGCAGCAAUUUGUTT-3&#x2032;.</p>
</sec>
<sec>
<title>Establishing a radioresistant cervical cancer cell line</title>
<p>Cells were cultured to 80&#x0025; confluence and then subjected to irradiation. Irradiation parameters were set as follows: Quality, 6 MV/X-rays; dose rate, 2 Gy/min; field, 35&#x00D7;35 cm; and 2 Gy each time, using a linear accelerator. Cells were kept at room temperature for &#x2264;30 min during irradiation. One set of flasks was not irradiated and treated as wild type. After 24 h of incubation, the medium in each flask was exchanged for fresh medium to remove detached cells. Cells resistant to radiation were cultured in the same medium, which was exchanged for fresh medium every 2 days thereafter. To generate stable radioresistant clones, all the clones after 60 Gy radiation were expanded for &#x003E;6 months without radiation to confirm the radioresistant phenotype before studies were undertaken. Two clones from C33A cells were established. The parental cells of wild-type stable clones were generated under the same conditions without irradiation.</p>
</sec>
<sec>
<title>Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and analysis</title>
<p>Total RNA was extracted from cell lines using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer&#x0027;s protocol. For the detection of miRNAs, RNA was reverse transcribed using a specific RT primer for U6 and miRNA-320 (Guangzhou RiboBio Co., Ltd.) according to the protocol of the manufacturer. qPCR was carried out with SYBR Green I Mix (Takara Biotechnology Co., Ltd., Dalian, China) in a 20-&#x00B5;l reaction volume (12.5 &#x00B5;l SYBR Green I Mix, 0.5 &#x00B5;l ROX reference dye II, 200 mM forward and reverse primer, 2 &#x00B5;l complementary DNA template and 8 &#x00B5;l double-distilled H<sub>2</sub>O) on the iCycler iQ Real-Time PCR Detection System (Bio-Rad Laboratories, Inc., Hercules, CA, USA) using the following protocol: 95&#x00B0;C for 20 sec, followed by 40 cycles of 95&#x00B0;C for 10 sec, 60&#x00B0;C for 20 sec and 70&#x00B0;C for 10 sec. The primers for miR-212/320/132/15a/16 for RT-qPCR were designed and synthesized by Guangzhou RiboBio Co., Ltd. The sequences for the remaining primers were as follows: &#x03B2;-catenin forward, 5&#x2032;-GAAACGGCTTTCAGTTGAGC-3&#x2032; and reverse, 5&#x2032;-CTGGCCATATCCACCAGAGT-3&#x2032;; c-MYC forward, 5&#x2032;-GGGTAGTGGAAAACCAGCAGC-3&#x2032; and reverse, 5&#x2032;-CCTCCTCGTCGCAGTAGAAATA-3&#x2032;; cyclin D1 forward, 5&#x2032;-GAGGAACAGAAGTGCGAGGAG-3&#x2032; and reverse, 5&#x2032;-GGATGGAGTTGTCGGTGTAGAT-3&#x2032;; and GAPDH forward, 5&#x2032;-TGGAAGGACTCATGACCACA-3&#x2032; and reverse, 5&#x2032;-TTCAGCTCAGGGATGACCTT-3&#x2032;. &#x2206; quantification cycle (Cq) was calculated by subtracting the Cq of U6 from the Cq of miRNA-320. &#x2206;&#x2206;Cq was then calculated by subtracting the &#x2206;Cq of the control from the &#x2206;Cq of the treatment group. The fold-change of miRNA expression was calculated by the equation 2<sup>&#x2212;&#x2206;&#x2206;Cq</sup> (<xref rid="b10-ol-0-0-5340" ref-type="bibr">10</xref>).</p>
</sec>
<sec>
<title>Flow cytometric analysis of cell cycle distribution</title>
<p>Cells were harvested and washed with cold PBS three times, fixed with 70&#x0025; ethanol at 4&#x00B0;C for 24 h, washed again three times with cold PBS and then stained with 50 mg/ml propidium iodide for 0.5 h at 37&#x00B0;C (Beyotime Institute of Biotechnology, Haimen, China). DNA content was analyzed on the Cytomics FC 500 (Beckman Coulter, Inc., Brea, CA, USA).</p>
</sec>
<sec>
<title>Colony-formation assay</title>
<p>Cells in an exponential growth phase were plated into a 6-well plate at 100, 200, 400, 800, 1,000 and 2,000 cells per well, and then irradiated with 0, 2, 4, 6, 8 and 10 Gy. Cells were then incubated at 37&#x00B0;C in 5&#x0025; CO<sub>2</sub>, 95&#x0025; air for 9&#x2013;12 days. When most cell clones had reached &#x003E;50 cells, they were stained with 0.5&#x0025; (w/v) crystal violet (Sigma-Aldrich; Merck Millipore, Darmstadt, Germany). The number of clones in the radioresistant group was compared with that in the wild-type group. The survival curves were obtained and analyzed with GraphPad Prism 4 statistical software (GraphPad Software, Inc., La Jolla, CA, USA). Three independent experiments were performed.</p>
</sec>
<sec>
<title>Cell proliferation assay</title>
<p>Cell proliferation was assessed using the WST-1 Cell Proliferation Reagent (Dojindo Molecular Technologies, Inc., Kumamoto, Japan), according to the manufacturer&#x0027;s protocol. The C33AR cells were plated into a 96-well cell culture plate at 2,000 cells/well and then incubated at 37&#x00B0;C overnight to allow settling. Then, they were transfected with miRNA-320 agomir and negative control, and treated with 4 Gy X-ray radiation. Subsequently, 10 &#x00B5;l of WST-1 reagent was added in each well and incubated for 2 h at 37&#x00B0;C. Absorbance was subsequently determined at a wavelength of 450 nm (for measurements) and 650 nm (as reference) by a microplate reader (EnSpire; PerkinElmer, Inc., Waltham, MA, USA). Cell proliferation was calculated by subtracting the absorbance values of the samples from that of the medium alone (background level). The relative cell proliferation was normalized to that of the control group.</p>
</sec>
<sec>
<title>&#x03B2;-catenin RNA interference in the cervical cancer radioresistant cell line C33AR</title>
<p>The &#x03B2;-catenin siRNA oligonucleotides with the sequence si-1 sense 5&#x2032;-GCAGUUGUAAACUUGAUUATT-3&#x2032;; si-2 sense 5&#x2032;-CCCAAGCUUUAGUAAAUAUTT-3&#x2032;; and si-3 sense 5&#x2032;-GGACACAGCAGCAAUUUGUTT-3&#x2032;, along with the corresponding antisense oligonucleotides, were synthesized by Shanghai GenePharma Co., Ltd. A negative control siRNA (Shanghai GenePharma Co., Ltd.) was used as a control siRNA. siRNA transfection was performed using Lipofectamine 2000 as indicated in the manufacturer&#x0027;s instructions. Briefly, subconfluent C33AR cells were plated in 6-well plates in regular growth medium. The next day, they were transfected with either 100 nM control siRNA or the &#x03B2;-catenin siRNAs for 6 h, followed by recovery in serum-containing medium. After 48 h of siRNAs transfection, the cells were harvested for protein isolation analysis.</p>
</sec>
<sec>
<title>Western blotting</title>
<p>Cells were washed with PBS and lysed in radioimmunoprecipitation assay buffer containing 50 mM Tris-HCl, 150 mM NaCl, 1&#x0025; NP-40, 0.1&#x0025; SDS, 0.5&#x0025; sodium deoxycholate, 2 mM sodium fluoride, 2 mM Na<sub>3</sub>VO<sub>4</sub>, 1 mM EDTA, 1 mM EGTA and a protease inhibitor cocktail (Roche Diagnostics, Basel, Switzerland). Cell lysates were quantified for protein content by the bicinchoninic acid (BCA) method using a BCA kit (Bio-Rad Laboratories, Inc.). Then, 40 &#x00B5;g of protein was resolved in 12&#x0025; SDS-PAGE and transferred onto a polyvinylidene fluoride membrane (EMD Millipore, Billerica, MA, USA). Membranes were blocked in 5&#x0025; bovine serum albumin (Beyotime Institute of Biotechnology) in TBS with Tween-20 (TBST) for 2 h, and then probed with primary antibodies against &#x03B2;-catenin (ab22656; Abcam, Cambridge, MA, USA), cyclin D1 (ab134175; Abcam), c-MYC (ab32072; Abcam) and GAPDH (KM1002T; Sungene Biotech Co., Ltd., Tianjin, China) at a 1:1,000 dilution at 4&#x00B0;C overnight, washed extensively with TBST three times, and incubated with secondary antibodies conjugated with horseradish peroxidase (Pierce; Thermo Fisher Scientific, Inc.)at room temperature for 2 h at a 1:5,000 dilution. Immunoreactive protein was examined using an enhanced chemiluminescence kit (Beyotime Institute of Biotechnology).</p>
</sec>
<sec>
<title>Statistical analysis</title>
<p>The results of the quantitative data in this study are expressed as the mean &#x00B1; standard deviation. The Student&#x0027;s <italic>t</italic>-test was used to evaluate the significant difference between two groups of data in all pertinent experiments with the statistical package SPSS 17.0 (SPSS, Inc., Chicago, IL, USA). P&#x003C;0.05 (using a two-tailed paired <italic>t</italic>-test) was considered to indicate a statistically significant difference between two groups of data.</p>
</sec>
</sec>
</sec>
<sec sec-type="results">
<title>Results</title>
<sec>
<title/>
<sec>
<title>Establishing and validating radioresistant C33AR cells</title>
<p>To generate a radioresistant cell line, C33A cells in exponential growth phase were exposed to X-rays at a dose of 2 Gy and a dose rate of 2 Gy/min. An interval of 1 to 3 weeks between each ionizing radiation (IR) allowed the surviving cells to regenerate. The whole process of IR and culture lasted for ~1 year, and the surviving cell line was termed C33AR. To verify phenotypes, C33AR cells were irradiated and examined by the colony-formation assay. Compared with C33A, C33AR showed no change in foci formation when IR was absent, but gained more foci and higher survival fractions when exposed to IR (<xref rid="f1-ol-0-0-5340" ref-type="fig">Fig. 1A</xref>), establishing C33AR as a stable radioresistant cell line. Next, flow cytometry was used to evaluate alterations in the cell cycle (<xref rid="f1-ol-0-0-5340" ref-type="fig">Fig. 1B and C</xref>). After irradiation, C33AR cells in the G1 and S phases significantly increased. Conversely, the proportion of C33AR in the G2/M phase decreased.</p>
</sec>
<sec>
<title>Differential expression of miRNAs and &#x03B2;-catenin in radioresistant cells</title>
<p>The differential miRNA expression profile between C33AR cells and their parental C33A cells was determined using RT-qPCR (<xref rid="f2-ol-0-0-5340" ref-type="fig">Fig. 2A</xref>). The expression of miRNA-320 in C33AR cells was significantly lower than that in C33A cells. Several differentially expressed miRNAs in this profile were previously reported to have a role in tumorigenesis, including the development of radioresistance (<xref rid="b17-ol-0-0-5340" ref-type="bibr">17</xref>,<xref rid="b18-ol-0-0-5340" ref-type="bibr">18</xref>). These results indicated that differentially expressed miRNAs may contribute to the acquisition of radioresistance in cervical cancer. The expression of miRNA-320 was significantly changed in cervical cancer cells after radiation. In addition, &#x03B2;-catenin was highly expressed in C33AR cells compared with C33A cells at the protein level but not at the messenger RNA level (<xref rid="f2-ol-0-0-5340" ref-type="fig">Fig. 2B and C</xref>).</p>
</sec>
<sec>
<title>miRNA-320 influences the sensitivity of C33AR and parental cells to irradiation</title>
<p>Based on the differential expression of miRNA-320 between C33AR and its parental C33A cells, the potential role of miRNA-320 in cervical cancer radiobiology was examined by overexpressing or repressing miRNA-320 using synthetic miRNA-320 agomir/antiagomir in C33AR and C33A cells, respectively. The expression of miRNA-320 was tested by RT-qPCR (<xref rid="f3-ol-0-0-5340" ref-type="fig">Fig. 3A and B</xref>). Following miRNA-320 overexpression, the survival rate of C33AR cells decreased compared with that of C33AR cells transfected with negative control vector 10 days after IR stimulation (<xref rid="f3-ol-0-0-5340" ref-type="fig">Fig. 3C</xref>). These results revealed that overexpression of miRNA-320 significantly increases the sensitivity of C33AR cells to irradiation. The expression of miRNA-320 in C33A cells was inhibited by being transfected with antiagomir, and caused a decrease in radiosensitivity (<xref rid="f3-ol-0-0-5340" ref-type="fig">Fig. 3D</xref>). In the proliferation assay, C33AR cells were transfected with miRNA-320 agomir and negative control, and exposed to IR with 4 Gy x-rays, and their cell growth was monitored by counting the cell numbers (<xref rid="f3-ol-0-0-5340" ref-type="fig">Fig. 3E</xref>). Increased expression of miRNA-320 promoted cell death in the experimental group with 4 Gy IR exposure in the long-term cell culture compared with the negative control.</p>
</sec>
<sec>
<title>Decrease in miRNA-320 induces the radioresistance of cervical cancer cells by targeting &#x03B2;-catenin expression</title>
<p>Hsieh <italic>et al</italic> have reported that miRNA-320 inhibits endogenous &#x03B2;-catenin expression and nuclear localization in prostate cancer (<xref rid="b19-ol-0-0-5340" ref-type="bibr">19</xref>). When &#x03B2;-catenin translocates to the nucleus, it activates the transcription of Wnt/&#x03B2;-catenin target genes, such as c-MYC and cyclin D1 (<xref rid="b20-ol-0-0-5340" ref-type="bibr">20</xref>). Therefore, to further explore the mechanism by which miRNA-320 influences cell radiosensitivity, the expression of &#x03B2;-catenin, c-MYC and cyclin D1 was examined by RT-qPCR and western blotting after transfecting C33AR cells with miRNA-320 agomir (<xref rid="f4-ol-0-0-5340" ref-type="fig">Fig. 4A, B and D</xref>). Upon transfection with miRNA-320 antiagomir in C33A cells, the expression of &#x03B2;-catenin increased at the protein level (<xref rid="f4-ol-0-0-5340" ref-type="fig">Fig. 4C</xref>). To confirm that miRNA-320 modulates the radiobiological behavior of cervical cancer cells by repressing &#x03B2;-catenin expression, rescue experiments were performed. First, &#x03B2;-catenin expression was inhibited using siRNAs (<xref rid="f4-ol-0-0-5340" ref-type="fig">Fig. 4E</xref>) and then, the knockdown of &#x03B2;-catenin increased C33AR radiosensitivity (<xref rid="f4-ol-0-0-5340" ref-type="fig">Fig. 4F</xref>). The inhibition of &#x03B2;-catenin rescued miRNA-320-mediated cell radioresistance. These results indicated that a decrease in miRNA-320 inhibits cervical cancer cell radiosensitivity <italic>in vitro</italic> by negatively regulating &#x03B2;-catenin expression and Wnt/&#x03B2;-catenin signaling activity.</p>
</sec>
</sec>
</sec>
<sec sec-type="discussion">
<title>Discussion</title>
<p>Radiotherapy is the main treatment for cervical cancer, especially at an early stage of the disease. However, many patients are not sufficiently radiosensitive and relapse soon after radiotherapy (<xref rid="b1-ol-0-0-5340" ref-type="bibr">1</xref>). The tumor radiation response is thus a major factor for the effect (and closely related to) tumor radiosensitivity. Numerous biological processes participate in the regulation of tumor radiation response, including DNA damage response and repair, cell cycle checkpoint, apoptosis control, and metabolism (<xref rid="b21-ol-0-0-5340" ref-type="bibr">21</xref>).</p>
<p>Although some achievements have been made in previous studies (<xref rid="b22-ol-0-0-5340" ref-type="bibr">22</xref>,<xref rid="b23-ol-0-0-5340" ref-type="bibr">23</xref>), the exact molecular mechanisms underlying radioresistance remain to be elucidated. In the past years, there has been increasing evidence regarding miRNAs as important regulators of radiotherapeutic resistance and other biological effects (<xref rid="b24-ol-0-0-5340" ref-type="bibr">24</xref>,<xref rid="b25-ol-0-0-5340" ref-type="bibr">25</xref>). In this study, a radioresistant cervical cancer cell line was identified using the clonogenic assay. Biological analyses revealed an increased percentage of G1-phase cells in the C33AR cell line compared with the parental cell line, suggesting its radioresistance, since it is generally accepted that cells are usually most sensitive to radiation in the late G2/M phase and most resistant to radiation in the mid-to-late S and early G1 phases (<xref rid="b26-ol-0-0-5340" ref-type="bibr">26</xref>).</p>
<p>The RT-qPCR results indicated that miRNA-320 was significantly decreased in the C33AR cell line. The <italic>in vitro</italic> functional analysis in our study demonstrated that a decrease in miRNA-320 confers radioresistance to the C33AR cell line, and that miRNA-320 overexpression induces increased radiosensitivity in C33AR cells. This alteration suggests that the differential expression of some miRNAs may be important for surviving the cytotoxic effects of radiation, thus supporting previous results demonstrated in other cancer types (<xref rid="b27-ol-0-0-5340" ref-type="bibr">27</xref>,<xref rid="b28-ol-0-0-5340" ref-type="bibr">28</xref>).</p>
<p>miRNA-320 is located on chromosome 8p21.3, a region frequently reported to undergo a loss of heterozygosity during the progression of prostate cancer (<xref rid="b29-ol-0-0-5340" ref-type="bibr">29</xref>). Altered miRNA-320 expression has also been linked to a defect in post-transcriptional processing and chromosomal deletions (<xref rid="b29-ol-0-0-5340" ref-type="bibr">29</xref>). The attenuation of miRNA-320 expression has also been demonstrated to be important for the initiation (<xref rid="b30-ol-0-0-5340" ref-type="bibr">30</xref>) and progression (<xref rid="b31-ol-0-0-5340" ref-type="bibr">31</xref>) of a number of cellular processes. The downregulation of miRNA-320 and the following radioresistant effect in C33AR cells support a critical role for this miRNA in modulating the cellular response to radiation. This is supported not only by the downregulation of miRNA-320 in our model but also in the larynx squamous carcinoma acquired radioresistant cell line Hep2R (<xref rid="b32-ol-0-0-5340" ref-type="bibr">32</xref>) in a previous study. However, the overexpression of miRNA-320 in the C33A cell line did not enhance radiosensitivity (data not shown). This may be explained by a plateau effect, given the relatively high basal expression of miRNA-320 in these cells, or it may suggest that the modulatory effect of miRNA-320 on the radiosensitivity of C33AR cells may depend on other molecular genetic changes that occurred during the generation of this radioresistant subline.</p>
<p>Radiation can induce different alterations in various oncogenes or cancer suppressor genes, including P53, Bcl-2-associated X protein, P21 and DNA-dependent protein kinase (<xref rid="b33-ol-0-0-5340" ref-type="bibr">33</xref>&#x2013;<xref rid="b35-ol-0-0-5340" ref-type="bibr">35</xref>). Therefore, bioinformatic algorithms, including PicTar (<uri xlink:href="http://pictar.bio.nyu.edu/">pictar.bio.nyu.edu/</uri>), <uri xlink:href="http://MicroRNA.org">MicroRNA.org</uri> (<uri xlink:href="http://www.microrna.org/microrna/home.do">www.microrna.org/microrna/home.do</uri>) and Targetscan (<uri xlink:href="http://www.targetscan.org/">www.targetscan.org/</uri>), were used to determine that &#x03B2;-catenin, a well-known oncogene (<xref rid="b36-ol-0-0-5340" ref-type="bibr">36</xref>), is a potential target with the highest predictive value for miRNA-320. In addition, a previous study confirmed it as a target of miRNA-320 (<xref rid="b19-ol-0-0-5340" ref-type="bibr">19</xref>). The study, performed in prostate cancer cells, demonstrated that miRNA-320 influences stem cell-like characteristics by directly downregulating the Wnt/&#x03B2;-catenin signaling pathway (<xref rid="b19-ol-0-0-5340" ref-type="bibr">19</xref>). In the present study, miRNA-320 was identified as a critical contributor to radioresistance by directly targeting &#x03B2;-catenin in cervical cancer. Previous studies have demonstrated that the activation of the Wnt signaling pathway is a key radioprotective mechanism in irradiated cancer cells (<xref rid="b37-ol-0-0-5340" ref-type="bibr">37</xref>&#x2013;<xref rid="b40-ol-0-0-5340" ref-type="bibr">40</xref>). Woodward <italic>et al</italic> reported that Wnt and &#x03B2;-catenin signaling may contribute to the radioresistance of breast cancer stem cells (<xref rid="b41-ol-0-0-5340" ref-type="bibr">41</xref>), and Watson <italic>et al</italic> reported that cells with silenced &#x03B2;-catenin are more sensitive to radiation compared with the parental cell line (<xref rid="b42-ol-0-0-5340" ref-type="bibr">42</xref>). The present report is the first to demonstrate an association between miRNA-320 downregulation and radioresistance through a negative regulation of &#x03B2;-catenin. Although the colony-formation assay confirmed that the differential expression of miRNA-320 and the inverse expression of &#x03B2;-catenin are related to radioresistance, it remains unclear how the miRNA-320/&#x03B2;-catenin signaling pathway participates in establishing radioresistance in cervical cancer. Further work is required to elucidate these factors and to assess their importance in the radiation response of cervical cancer.</p>
<p>As traditional radiotherapy may result in the potential radioresistance of cervical cancer, the classical schedule requires a radiosensitive drug regimen to enhance its curative effect. The roles of miRNAs in the regulation of tumor radiosensitivity suggest that miRNAs will be a promising target for clinical diagnosis and treatment. In addition, the potential improvement of radiotherapeutic effects through activating or inhibiting the expression of certain miRNAs and downstream target genes is extremely promising. A thorough understanding of tumor radiosensitivity and the regulatory mechanisms of miRNAs will bring new hope to more cancer patients.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgements</title>
<p>We thank the support provided by the National Natural Science Foundation of China (Beijing, China; grant nos. 81071908 and 81272996) and the Fundamental Research Funds for the Central Universities (Hubei, China; grant no. 2042014).</p>
</ack>
<ref-list>
<title>References</title>
<ref id="b1-ol-0-0-5340"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parkin</surname><given-names>DM</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Pisani</surname><given-names>P</given-names></name></person-group><article-title>Global cancer statistics, 2002</article-title><source>CA Cancer J Clin</source><volume>55</volume><fpage>74</fpage><lpage>108</lpage><year>2005</year><pub-id pub-id-type="doi">10.3322/canjclin.55.2.74</pub-id><pub-id pub-id-type="pmid">15761078</pub-id></element-citation></ref>
<ref id="b2-ol-0-0-5340"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waggoner</surname><given-names>SE</given-names></name></person-group><article-title>Cervical cancer</article-title><source>Lancet</source><volume>361</volume><fpage>2217</fpage><lpage>2225</lpage><year>2003</year><pub-id pub-id-type="doi">10.1016/S0140-6736(03)13778-6</pub-id><pub-id pub-id-type="pmid">12842378</pub-id></element-citation></ref>
<ref id="b3-ol-0-0-5340"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernstein</surname><given-names>E</given-names></name><name><surname>Caudy</surname><given-names>AA</given-names></name><name><surname>Hammond</surname><given-names>SM</given-names></name><name><surname>Hannon</surname><given-names>GJ</given-names></name></person-group><article-title>Role for a bidentate ribonuclease in the initiation step of RNA interference</article-title><source>Nature</source><volume>409</volume><fpage>363</fpage><lpage>366</lpage><year>2001</year><pub-id pub-id-type="doi">10.1038/35053110</pub-id><pub-id pub-id-type="pmid">11201747</pub-id></element-citation></ref>
<ref id="b4-ol-0-0-5340"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sevignani</surname><given-names>C</given-names></name><name><surname>Calin</surname><given-names>GA</given-names></name><name><surname>Siracusa</surname><given-names>LD</given-names></name><name><surname>Croce</surname><given-names>CM</given-names></name></person-group><article-title>Mammalian microRNAs: A small world for fine-tuning gene expression</article-title><source>Mamm Genome</source><volume>17</volume><fpage>189</fpage><lpage>202</lpage><year>2006</year><pub-id pub-id-type="doi">10.1007/s00335-005-0066-3</pub-id><pub-id pub-id-type="pmid">16518686</pub-id></element-citation></ref>
<ref id="b5-ol-0-0-5340"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Pan</surname><given-names>X</given-names></name></person-group><article-title>MicroRNAs and their regulatory roles in animals and plants</article-title><source>J Cell Physiol</source><volume>210</volume><fpage>279</fpage><lpage>289</lpage><year>2007</year><pub-id pub-id-type="doi">10.1002/jcp.20869</pub-id><pub-id pub-id-type="pmid">17096367</pub-id></element-citation></ref>
<ref id="b6-ol-0-0-5340"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mendell</surname><given-names>JT</given-names></name><name><surname>Olson</surname><given-names>EN</given-names></name></person-group><article-title>MicroRNAs in stress signaling and human disease</article-title><source>Cell</source><volume>148</volume><fpage>1172</fpage><lpage>1187</lpage><year>2012</year><pub-id pub-id-type="doi">10.1016/j.cell.2012.02.005</pub-id><pub-id pub-id-type="pmid">22424228</pub-id></element-citation></ref>
<ref id="b7-ol-0-0-5340"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nikitina</surname><given-names>EG</given-names></name><name><surname>Urazova</surname><given-names>LN</given-names></name><name><surname>Stegny</surname><given-names>VN</given-names></name></person-group><article-title>MicroRNAs and human cancer</article-title><source>Exp Oncol</source><volume>34</volume><fpage>2</fpage><lpage>8</lpage><year>2012</year><pub-id pub-id-type="pmid">22453141</pub-id></element-citation></ref>
<ref id="b8-ol-0-0-5340"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>H</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Caramuta</surname><given-names>S</given-names></name><name><surname>Larsson</surname><given-names>C</given-names></name><name><surname>Lui</surname><given-names>WO</given-names></name></person-group><article-title>miR-205 expression promotes cell proliferation and migration of human cervical cancer cells</article-title><source>PLoS One</source><volume>7</volume><fpage>e46990</fpage><year>2012</year><pub-id pub-id-type="doi">10.1371/journal.pone.0046990</pub-id><pub-id pub-id-type="pmid">23056551</pub-id></element-citation></ref>
<ref id="b9-ol-0-0-5340"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aigner</surname><given-names>A</given-names></name></person-group><article-title>MicroRNAs (miRNAs) in cancer invasion and metastasis: Therapeutic approaches based on metastasis-related miRNAs</article-title><source>J Mol Med (Berl)</source><volume>89</volume><fpage>445</fpage><lpage>457</lpage><year>2011</year><pub-id pub-id-type="doi">10.1007/s00109-010-0716-0</pub-id><pub-id pub-id-type="pmid">21234533</pub-id></element-citation></ref>
<ref id="b10-ol-0-0-5340"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Luo</surname><given-names>D</given-names></name><name><surname>Su</surname><given-names>K</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Tian</surname><given-names>Y</given-names></name><name><surname>Wei</surname><given-names>L</given-names></name></person-group><article-title>MicroRNA-610 inhibits the migration and invasion of gastric cancer cells by suppressing the expression of vasodilator-stimulated phosphoprotein</article-title><source>Eur J Cancer</source><volume>48</volume><fpage>1904</fpage><lpage>1913</lpage><year>2012</year><pub-id pub-id-type="doi">10.1016/j.ejca.2011.11.026</pub-id><pub-id pub-id-type="pmid">22189055</pub-id></element-citation></ref>
<ref id="b11-ol-0-0-5340"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>LY</given-names></name><name><surname>Ho-Fun Lee</surname><given-names>V</given-names></name><name><surname>Wong</surname><given-names>AM</given-names></name><name><surname>Kwong</surname><given-names>DL</given-names></name><name><surname>Zhu</surname><given-names>YH</given-names></name><name><surname>Dong</surname><given-names>SS</given-names></name><name><surname>Kong</surname><given-names>KL</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Tsao</surname><given-names>SW</given-names></name><name><surname>Guan</surname><given-names>XY</given-names></name><name><surname>Fu</surname><given-names>L</given-names></name></person-group><article-title>MicroRNA-144 promotes cell proliferation, migration and invasion in nasopharyngeal carcinoma through repression of PTEN</article-title><source>Carcinogenesis</source><volume>34</volume><fpage>454</fpage><lpage>463</lpage><year>2013</year><pub-id pub-id-type="doi">10.1093/carcin/bgs346</pub-id><pub-id pub-id-type="pmid">23125220</pub-id></element-citation></ref>
<ref id="b12-ol-0-0-5340"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lynam-Lennon</surname><given-names>N</given-names></name><name><surname>Reynolds</surname><given-names>JV</given-names></name><name><surname>Marignol</surname><given-names>L</given-names></name><name><surname>Sheils</surname><given-names>OM</given-names></name><name><surname>Pidgeon</surname><given-names>GP</given-names></name><name><surname>Maher</surname><given-names>SG</given-names></name></person-group><article-title>MicroRNA-31 modulates tumour sensitivity to radiation in oesophageal adenocarcinoma</article-title><source>J Mol Med (Berl)</source><volume>90</volume><fpage>1449</fpage><lpage>1458</lpage><year>2012</year><pub-id pub-id-type="doi">10.1007/s00109-012-0924-x</pub-id><pub-id pub-id-type="pmid">22706599</pub-id></element-citation></ref>
<ref id="b13-ol-0-0-5340"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Zhu</surname><given-names>W</given-names></name><name><surname>Shi</surname><given-names>D</given-names></name><name><surname>Lv</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>P</given-names></name><name><surname>Hu</surname><given-names>W</given-names></name></person-group><article-title>MicroRNA-181a sensitizes human malignant glioma U87MG cells to radiation by targeting Bcl-2</article-title><source>Oncol Rep</source><volume>23</volume><fpage>997</fpage><lpage>1003</lpage><year>2010</year><pub-id pub-id-type="pmid">20204284</pub-id></element-citation></ref>
<ref id="b14-ol-0-0-5340"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Su</surname><given-names>Z</given-names></name><name><surname>Ren</surname><given-names>S</given-names></name><name><surname>Zhu</surname><given-names>G</given-names></name><name><surname>Tian</surname><given-names>Y</given-names></name><name><surname>Qiu</surname><given-names>Y</given-names></name></person-group><article-title>MicroRNA-324-3p regulates nasopharyngeal carcinoma radioresistance by directly targeting WNT2B</article-title><source>Eur J Cancer</source><volume>49</volume><fpage>2596</fpage><lpage>2607</lpage><year>2013</year><pub-id pub-id-type="doi">10.1016/j.ejca.2013.03.001</pub-id><pub-id pub-id-type="pmid">23583221</pub-id></element-citation></ref>
<ref id="b15-ol-0-0-5340"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salim</surname><given-names>H</given-names></name><name><surname>Akbar</surname><given-names>NS</given-names></name><name><surname>Zong</surname><given-names>D</given-names></name><name><surname>Vaculova</surname><given-names>AH</given-names></name><name><surname>Lewensohn</surname><given-names>R</given-names></name><name><surname>Moshfegh</surname><given-names>A</given-names></name><name><surname>Viktorsson</surname><given-names>K</given-names></name><name><surname>Zhivotovsky</surname><given-names>B</given-names></name></person-group><article-title>miRNA-214 modulates radiotherapy response of non-small cell lung cancer cells through regulation of p38MAPK, apoptosis and senescence</article-title><source>Br J Cancer</source><volume>107</volume><fpage>1361</fpage><lpage>1373</lpage><year>2012</year><pub-id pub-id-type="doi">10.1038/bjc.2012.382</pub-id><pub-id pub-id-type="pmid">22929890</pub-id></element-citation></ref>
<ref id="b16-ol-0-0-5340"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shinohara</surname><given-names>A</given-names></name><name><surname>Yokoyama</surname><given-names>Y</given-names></name><name><surname>Wan</surname><given-names>X</given-names></name><name><surname>Takahashi</surname><given-names>Y</given-names></name><name><surname>Mori</surname><given-names>Y</given-names></name><name><surname>Takami</surname><given-names>T</given-names></name><name><surname>Shimokawa</surname><given-names>K</given-names></name><name><surname>Tamaya</surname><given-names>T</given-names></name></person-group><article-title>Cytoplasmic/nuclear expression without mutation of exon 3 of the beta-catenin gene is frequent in the development of the neoplasm of the uterine cervix</article-title><source>Gynecol Oncol</source><volume>82</volume><fpage>450</fpage><lpage>455</lpage><year>2001</year><pub-id pub-id-type="doi">10.1006/gyno.2001.6298</pub-id><pub-id pub-id-type="pmid">11520139</pub-id></element-citation></ref>
<ref id="b17-ol-0-0-5340"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mei</surname><given-names>Z</given-names></name><name><surname>Su</surname><given-names>T</given-names></name><name><surname>Ye</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Xie</surname><given-names>C</given-names></name></person-group><article-title>The miR-15 family enhances the radiosensitivity of breast cancer cells by targeting G2 checkpoints</article-title><source>Radiat Res</source><volume>183</volume><fpage>196</fpage><lpage>207</lpage><year>2015</year><pub-id pub-id-type="doi">10.1667/RR13784.1</pub-id><pub-id pub-id-type="pmid">25594541</pub-id></element-citation></ref>
<ref id="b18-ol-0-0-5340"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Qi</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Luo</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name></person-group><article-title>Upregulation of the miR-212/132 cluster suppresses proliferation of human lung cancer cells</article-title><source>Oncol Rep</source><volume>33</volume><fpage>705</fpage><lpage>712</lpage><year>2015</year><pub-id pub-id-type="pmid">25435090</pub-id></element-citation></ref>
<ref id="b19-ol-0-0-5340"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsieh</surname><given-names>IS</given-names></name><name><surname>Chang</surname><given-names>KC</given-names></name><name><surname>Tsai</surname><given-names>YT</given-names></name><name><surname>Ke</surname><given-names>JY</given-names></name><name><surname>Lu</surname><given-names>PJ</given-names></name><name><surname>Lee</surname><given-names>KH</given-names></name><name><surname>Yeh</surname><given-names>SD</given-names></name><name><surname>Hong</surname><given-names>TM</given-names></name><name><surname>Chen</surname><given-names>YL</given-names></name></person-group><article-title>MicroRNA-320 suppresses the stem cell-like characteristics of prostate cancer cells by downregulating the Wnt/beta-catenin signaling pathway</article-title><source>Carcinogenesis</source><volume>34</volume><fpage>530</fpage><lpage>538</lpage><year>2013</year><pub-id pub-id-type="doi">10.1093/carcin/bgs371</pub-id><pub-id pub-id-type="pmid">23188675</pub-id></element-citation></ref>
<ref id="b20-ol-0-0-5340"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valenta</surname><given-names>T</given-names></name><name><surname>Hausmann</surname><given-names>G</given-names></name><name><surname>Basler</surname><given-names>K</given-names></name></person-group><article-title>The many faces and functions of &#x03B2;-catenin</article-title><source>Embo J</source><volume>31</volume><fpage>2714</fpage><lpage>2736</lpage><year>2012</year><pub-id pub-id-type="doi">10.1038/emboj.2012.150</pub-id><pub-id pub-id-type="pmid">22617422</pub-id></element-citation></ref>
<ref id="b21-ol-0-0-5340"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name></person-group><article-title>MicroRNA and signal transduction pathways in tumor radiation response</article-title><source>Cell Signal</source><volume>25</volume><fpage>1625</fpage><lpage>1634</lpage><year>2013</year><pub-id pub-id-type="doi">10.1016/j.cellsig.2013.04.004</pub-id><pub-id pub-id-type="pmid">23602933</pub-id></element-citation></ref>
<ref id="b22-ol-0-0-5340"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>L&#x00F3;pez</surname><given-names>J</given-names></name><name><surname>Poitevin</surname><given-names>A</given-names></name><name><surname>Mendoza-Mart&#x00ED;nez</surname><given-names>V</given-names></name><name><surname>P&#x00E9;rez-Plasencia</surname><given-names>C</given-names></name><name><surname>Garc&#x00ED;a-Carranc&#x00E1;</surname><given-names>A</given-names></name></person-group><article-title>Cancer-initiating cells derived from established cervical cell lines exhibit stem-cell markers and increased radioresistance</article-title><source>BMC Cancer</source><volume>12</volume><fpage>48</fpage><year>2012</year><pub-id pub-id-type="doi">10.1186/1471-2407-12-48</pub-id><pub-id pub-id-type="pmid">22284662</pub-id></element-citation></ref>
<ref id="b23-ol-0-0-5340"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ke</surname><given-names>G</given-names></name><name><surname>Liang</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>JM</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Han</surname><given-names>D</given-names></name><name><surname>Huang</surname><given-names>S</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Zha</surname><given-names>R</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name></person-group><article-title>MiR-181a confers resistance of cervical cancer to radiation therapy through targeting the pro-apoptotic PRKCD gene</article-title><source>Oncogene</source><volume>32</volume><fpage>3019</fpage><lpage>3027</lpage><year>2013</year><pub-id pub-id-type="doi">10.1038/onc.2012.323</pub-id><pub-id pub-id-type="pmid">22847611</pub-id></element-citation></ref>
<ref id="b24-ol-0-0-5340"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>XM</given-names></name><name><surname>Wang</surname><given-names>XB</given-names></name><name><surname>Chen</surname><given-names>MM</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>YX</given-names></name><name><surname>Jia</surname><given-names>WH</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Tang</surname><given-names>H</given-names></name></person-group><article-title>MicroRNA-19a and &#x2212;19b regulate cervical carcinoma cell proliferation and invasion by targeting CUL5</article-title><source>Cancer Lett</source><volume>322</volume><fpage>148</fpage><lpage>158</lpage><year>2012</year><pub-id pub-id-type="doi">10.1016/j.canlet.2012.02.038</pub-id><pub-id pub-id-type="pmid">22561557</pub-id></element-citation></ref>
<ref id="b25-ol-0-0-5340"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>T</given-names></name><name><surname>Wong</surname><given-names>HK</given-names></name><name><surname>Gu</surname><given-names>W</given-names></name><name><surname>Yu</surname><given-names>MY</given-names></name><name><surname>To</surname><given-names>KF</given-names></name><name><surname>Wang</surname><given-names>CC</given-names></name><name><surname>Wong</surname><given-names>YF</given-names></name><name><surname>Cheung</surname><given-names>TH</given-names></name><name><surname>Chung</surname><given-names>TK</given-names></name><name><surname>Choy</surname><given-names>KW</given-names></name></person-group><article-title>MicroRNA-182 plays an onco-miRNA role in cervical cancer</article-title><source>Gynecol Oncol</source><volume>129</volume><fpage>199</fpage><lpage>208</lpage><year>2013</year><pub-id pub-id-type="doi">10.1016/j.ygyno.2012.12.043</pub-id><pub-id pub-id-type="pmid">23313739</pub-id></element-citation></ref>
<ref id="b26-ol-0-0-5340"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pawlik</surname><given-names>TM</given-names></name><name><surname>Keyomarsi</surname><given-names>K</given-names></name></person-group><article-title>Role of cell cycle in mediating sensitivity to radiotherapy</article-title><source>Int J Radiat Oncol Biol Phys</source><volume>59</volume><fpage>928</fpage><lpage>942</lpage><year>2004</year><pub-id pub-id-type="doi">10.1016/j.ijrobp.2004.03.005</pub-id><pub-id pub-id-type="pmid">15234026</pub-id></element-citation></ref>
<ref id="b27-ol-0-0-5340"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shiiba</surname><given-names>M</given-names></name><name><surname>Shinozuka</surname><given-names>K</given-names></name><name><surname>Saito</surname><given-names>K</given-names></name><name><surname>Fushimi</surname><given-names>K</given-names></name><name><surname>Kasamatsu</surname><given-names>A</given-names></name><name><surname>Ogawara</surname><given-names>K</given-names></name><name><surname>Uzawa</surname><given-names>K</given-names></name><name><surname>Ito</surname><given-names>H</given-names></name><name><surname>Takiguchi</surname><given-names>Y</given-names></name><name><surname>Tanzawa</surname><given-names>H</given-names></name></person-group><article-title>MicroRNA-125b regulates proliferation and radioresistance of oral squamous cell carcinoma</article-title><source>Br J Cancer</source><volume>108</volume><fpage>1817</fpage><lpage>1821</lpage><year>2013</year><pub-id pub-id-type="doi">10.1038/bjc.2013.175</pub-id><pub-id pub-id-type="pmid">23591197</pub-id></element-citation></ref>
<ref id="b28-ol-0-0-5340"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>John-Aryankalayil</surname><given-names>M</given-names></name><name><surname>Palayoor</surname><given-names>ST</given-names></name><name><surname>Makinde</surname><given-names>AY</given-names></name><name><surname>Cerna</surname><given-names>D</given-names></name><name><surname>Simone</surname><given-names>CB</given-names><suffix>II</suffix></name><name><surname>Falduto</surname><given-names>MT</given-names></name><name><surname>Magnuson</surname><given-names>SR</given-names></name><name><surname>Coleman</surname><given-names>CN</given-names></name></person-group><article-title>Fractionated radiation alters oncomir and tumor suppressor miRNAs in human prostate cancer cells</article-title><source>Radiat Res</source><volume>178</volume><fpage>105</fpage><lpage>117</lpage><year>2012</year><pub-id pub-id-type="doi">10.1667/RR2703.1</pub-id><pub-id pub-id-type="pmid">22827214</pub-id></element-citation></ref>
<ref id="b29-ol-0-0-5340"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kagan</surname><given-names>J</given-names></name><name><surname>Stein</surname><given-names>J</given-names></name><name><surname>Babaian</surname><given-names>RJ</given-names></name><name><surname>Joe</surname><given-names>YS</given-names></name><name><surname>Pisters</surname><given-names>LL</given-names></name><name><surname>Glassman</surname><given-names>AB</given-names></name><name><surname>von Eschenbach</surname><given-names>AC</given-names></name><name><surname>Troncoso</surname><given-names>P</given-names></name></person-group><article-title>Homozygous deletions at 8p22 and 8p21 in prostate cancer implicate these regions as the sites for candidate tumor suppressor genes</article-title><source>Oncogene</source><volume>11</volume><fpage>2121</fpage><lpage>2126</lpage><year>1995</year><pub-id pub-id-type="pmid">7478532</pub-id></element-citation></ref>
<ref id="b30-ol-0-0-5340"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>BM</given-names></name><name><surname>Choi</surname><given-names>MY</given-names></name></person-group><article-title>Non-canonical microRNAs miR-320 and miR-702 promote proliferation in Dgcr8-deficient embryonic stem cells</article-title><source>Biochem Biophys Res Commun</source><volume>426</volume><fpage>183</fpage><lpage>189</lpage><year>2012</year><pub-id pub-id-type="doi">10.1016/j.bbrc.2012.08.058</pub-id><pub-id pub-id-type="pmid">22925886</pub-id></element-citation></ref>
<ref id="b31-ol-0-0-5340"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>XP</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Sartor</surname><given-names>MA</given-names></name><name><surname>Qian</surname><given-names>J</given-names></name><name><surname>Jones</surname><given-names>K</given-names></name><name><surname>Nicolaou</surname><given-names>P</given-names></name><name><surname>Pritchard</surname><given-names>TJ</given-names></name><name><surname>Fan</surname><given-names>GC</given-names></name></person-group><article-title>MicroRNA-320 is involved in the regulation of cardiac ischemia/reperfusion injury by targeting heat-shock protein 20</article-title><source>Circulation</source><volume>119</volume><fpage>2357</fpage><lpage>2366</lpage><year>2009</year><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.108.814145</pub-id><pub-id pub-id-type="pmid">19380620</pub-id></element-citation></ref>
<ref id="b32-ol-0-0-5340"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>FX</given-names></name><name><surname>Xiong</surname><given-names>J</given-names></name><name><surname>Luo</surname><given-names>ZG</given-names></name><name><surname>Dai</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>HJ</given-names></name><name><surname>Liao</surname><given-names>ZK</given-names></name><name><surname>Lei</surname><given-names>H</given-names></name><name><surname>Xie</surname><given-names>CH</given-names></name><name><surname>Zhou</surname><given-names>YF</given-names></name></person-group><article-title>cDNA expression analysis of a human radiosensitive-radioresistant cell line model identifies telomere function as a hallmark of radioresistance</article-title><source>Radiat Res</source><volume>174</volume><fpage>550</fpage><lpage>557</lpage><year>2010</year><pub-id pub-id-type="doi">10.1667/RR1657.1</pub-id><pub-id pub-id-type="pmid">20726715</pub-id></element-citation></ref>
<ref id="b33-ol-0-0-5340"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Atkinson</surname><given-names>RL</given-names></name><name><surname>Rosen</surname><given-names>JM</given-names></name></person-group><article-title>Selective targeting of radiation-resistant tumor-initiating cells</article-title><source>Proc Natl Acad Sci USA</source><volume>107</volume><fpage>3522</fpage><lpage>3527</lpage><year>2010</year><pub-id pub-id-type="doi">10.1073/pnas.0910179107</pub-id><pub-id pub-id-type="pmid">20133717</pub-id></element-citation></ref>
<ref id="b34-ol-0-0-5340"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Theys</surname><given-names>J</given-names></name><name><surname>Yahyanejad</surname><given-names>S</given-names></name><name><surname>Habets</surname><given-names>R</given-names></name><name><surname>Span</surname><given-names>P</given-names></name><name><surname>Dubois</surname><given-names>L</given-names></name><name><surname>Paesmans</surname><given-names>K</given-names></name><name><surname>Kattenbeld</surname><given-names>B</given-names></name><name><surname>Cleutjens</surname><given-names>J</given-names></name><name><surname>Groot</surname><given-names>AJ</given-names></name><name><surname>Schuurbiers</surname><given-names>OC</given-names></name><etal/></person-group><article-title>High NOTCH activity induces radiation resistance in non small cell lung cancer</article-title><source>Radiother Oncol</source><volume>108</volume><fpage>440</fpage><lpage>445</lpage><year>2013</year><pub-id pub-id-type="doi">10.1016/j.radonc.2013.06.020</pub-id><pub-id pub-id-type="pmid">23891097</pub-id></element-citation></ref>
<ref id="b35-ol-0-0-5340"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huerta</surname><given-names>S</given-names></name><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Dineen</surname><given-names>S</given-names></name><name><surname>Kapur</surname><given-names>P</given-names></name><name><surname>Saha</surname><given-names>D</given-names></name><name><surname>Meyer</surname><given-names>J</given-names></name></person-group><article-title>Role of p53, Bax, p21 and DNA-PKcs in radiation sensitivity of HCT-116 cells and xenografts</article-title><source>Surgery</source><volume>154</volume><fpage>143</fpage><lpage>151</lpage><year>2013</year><pub-id pub-id-type="doi">10.1016/j.surg.2013.03.012</pub-id><pub-id pub-id-type="pmid">23889944</pub-id></element-citation></ref>
<ref id="b36-ol-0-0-5340"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>KH</given-names></name><name><surname>Seol</surname><given-names>HJ</given-names></name><name><surname>Kim</surname><given-names>EH</given-names></name><name><surname>Rheey</surname><given-names>J</given-names></name><name><surname>Jin</surname><given-names>JH</given-names></name><name><surname>Lee</surname><given-names>Y</given-names></name><name><surname>Joo</surname><given-names>KM</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Nam</surname><given-names>DH</given-names></name></person-group><article-title>Wnt/&#x03B2;-catenin signaling is a key downstream mediator of MET signaling in glioblastoma stem cells</article-title><source>Neuro Oncol</source><volume>15</volume><fpage>161</fpage><lpage>171</lpage><year>2013</year><pub-id pub-id-type="doi">10.1093/neuonc/nos299</pub-id><pub-id pub-id-type="pmid">23258844</pub-id></element-citation></ref>
<ref id="b37-ol-0-0-5340"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orford</surname><given-names>K</given-names></name><name><surname>Orford</surname><given-names>CC</given-names></name><name><surname>Byers</surname><given-names>SW</given-names></name></person-group><article-title>Exogenous expression of beta-catenin regulates contact inhibition, anchorage-independent growth, anoikis, and radiation-induced cell cycle arrest</article-title><source>J Cell Biol</source><volume>146</volume><fpage>855</fpage><lpage>868</lpage><year>1999</year><pub-id pub-id-type="doi">10.1083/jcb.146.4.855</pub-id><pub-id pub-id-type="pmid">10459019</pub-id></element-citation></ref>
<ref id="b38-ol-0-0-5340"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakashima</surname><given-names>M</given-names></name><name><surname>Meirmanov</surname><given-names>S</given-names></name><name><surname>Matsufuji</surname><given-names>R</given-names></name><name><surname>Hayashida</surname><given-names>M</given-names></name><name><surname>Fukuda</surname><given-names>E</given-names></name><name><surname>Naito</surname><given-names>S</given-names></name><name><surname>Matsuu</surname><given-names>M</given-names></name><name><surname>Shichijo</surname><given-names>K</given-names></name><name><surname>Kondo</surname><given-names>H</given-names></name><name><surname>Ito</surname><given-names>M</given-names></name><etal/></person-group><article-title>Altered expression of beta-catenin during radiation-induced colonic carcinogenesis</article-title><source>Pathol Res Pract</source><volume>198</volume><fpage>717</fpage><lpage>724</lpage><year>2002</year><pub-id pub-id-type="doi">10.1078/0344-0338-00326</pub-id><pub-id pub-id-type="pmid">12530573</pub-id></element-citation></ref>
<ref id="b39-ol-0-0-5340"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodningen</surname><given-names>OK</given-names></name><name><surname>Overgaard</surname><given-names>J</given-names></name><name><surname>Alsner</surname><given-names>J</given-names></name><name><surname>Hastie</surname><given-names>T</given-names></name><name><surname>B&#x00F8;rresen-Dale</surname><given-names>AL</given-names></name></person-group><article-title>Microarray analysis of the transcriptional response to single or multiple doses of ionizing radiation in human subcutaneous fibroblasts</article-title><source>Radiother Oncol</source><volume>77</volume><fpage>231</fpage><lpage>240</lpage><year>2005</year><pub-id pub-id-type="doi">10.1016/j.radonc.2005.09.020</pub-id><pub-id pub-id-type="pmid">16297999</pub-id></element-citation></ref>
<ref id="b40-ol-0-0-5340"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gassler</surname><given-names>N</given-names></name><name><surname>Herr</surname><given-names>I</given-names></name><name><surname>Keith</surname><given-names>M</given-names></name><name><surname>Autschbach</surname><given-names>F</given-names></name><name><surname>Schmitz-Winnenthal</surname><given-names>H</given-names></name><name><surname>Ulrich</surname><given-names>A</given-names></name><name><surname>Otto</surname><given-names>HF</given-names></name><name><surname>Kartenbeck</surname><given-names>J</given-names></name><name><surname>Z&#x0027;graggen</surname><given-names>K</given-names></name></person-group><article-title>Wnt-signaling and apoptosis after neoadjuvant short-term radiotherapy for rectal cancer</article-title><source>Int J Oncol</source><volume>25</volume><fpage>1543</fpage><lpage>1549</lpage><year>2004</year><pub-id pub-id-type="pmid">15547689</pub-id></element-citation></ref>
<ref id="b41-ol-0-0-5340"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woodward</surname><given-names>WA</given-names></name><name><surname>Chen</surname><given-names>MS</given-names></name><name><surname>Behbod</surname><given-names>F</given-names></name><name><surname>Alfaro</surname><given-names>MP</given-names></name><name><surname>Buchholz</surname><given-names>TA</given-names></name><name><surname>Rosen</surname><given-names>JM</given-names></name></person-group><article-title>WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells</article-title><source>Proc Natl Acad Sci USA</source><volume>104</volume><fpage>618</fpage><lpage>623</lpage><year>2007</year><pub-id pub-id-type="doi">10.1073/pnas.0606599104</pub-id><pub-id pub-id-type="pmid">17202265</pub-id></element-citation></ref>
<ref id="b42-ol-0-0-5340"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watson</surname><given-names>RL</given-names></name><name><surname>Spalding</surname><given-names>AC</given-names></name><name><surname>Zielske</surname><given-names>SP</given-names></name><name><surname>Morgan</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>AC</given-names></name><name><surname>Bommer</surname><given-names>GT</given-names></name><name><surname>Eldar-Finkelman</surname><given-names>H</given-names></name><name><surname>Giordano</surname><given-names>T</given-names></name><name><surname>Fearon</surname><given-names>ER</given-names></name><name><surname>Hammer</surname><given-names>GD</given-names></name><etal/></person-group><article-title>GSK3beta and beta-catenin modulate radiation cytotoxicity in pancreatic cancer</article-title><source>Neoplasia</source><volume>12</volume><fpage>357</fpage><lpage>365</lpage><year>2010</year><pub-id pub-id-type="doi">10.1593/neo.92112</pub-id><pub-id pub-id-type="pmid">20454507</pub-id></element-citation></ref>
</ref-list>
</back>
<floats-group>
<fig id="f1-ol-0-0-5340" position="float">
<label>Figure 1.</label>
<caption><p>Establishing and validating radioresistant C33AR cells. The acquired radioresistant cell line C33AR was examined for its radiobiological characteristics. (A) Survival curves of C33A and C33AR cells. Cell surviving fractions were normalized to the plating efficiency of non-irradiated cells. &#x002A;&#x002A;P&#x003C;0.05. (B) The percentage of cells in each cell cycle phase of C33A and C33AR cells following 4 Gy X-ray radiation. (C) Cell cycle distribution of C33A and C33AR cells after 4 Gy X-ray radiation. Error bars represent SD. Means &#x00B1; SD are representative of three independent experiments. SD, standard deviation.</p></caption>
<graphic xlink:href="ol-12-06-4983-g00.jpg"/>
</fig>
<fig id="f2-ol-0-0-5340" position="float">
<label>Figure 2.</label>
<caption><p>Differential expression of miRNAs and &#x03B2;-catenin in radioresistant cells. Expression profiles of miRNAs and &#x03B2;-catenin in C33A and C33AR cervical cell lines. (A) The expression of miRNAs, as analyzed by reverse transcription-quantitative polymerase chain reaction and relative to U6, was different between parental cells C33A and radioresistant cells C33AR. (B) &#x03B2;-catenin mRNA expression was measured using GAPDH as an internal control, and no significant difference was observed between C33A and C33AR. (C) The expression of &#x03B2;-catenin protein was assessed by western blotting, and was observed to be increased in C33AR compared with C33A. The data were expressed as means &#x00B1; standard deviation (&#x002A;&#x002A;P&#x003C;0.05, Student&#x0027;s <italic>t</italic>-test). miRNA, microRNA.</p></caption>
<graphic xlink:href="ol-12-06-4983-g01.jpg"/>
</fig>
<fig id="f3-ol-0-0-5340" position="float">
<label>Figure 3.</label>
<caption><p>miRNA-320 influences the sensitivity of C33AR and parental cells to irradiation. Overexpression or repression of miRNA-320 in C33AR and its parental C33A influences the sensitivity of the cells to irradiation. (A and B) The expression of miRNA-320 was examined by reverse transcription-quantitative polymerase chain reaction after transfection of miRNA-320 agomir/antiagomir in (A) C33AR and (B) C33A cells. (C) miRNA-320 overexpression in C33AR cells results in increased radiosensitivity. (D) The expression of miRNA-320 was inhibited in C33A cells and caused a decrease in radiosensitivity. Quantitative measurement of colony formation in each cell group. (E) Proliferation of C33AR cells after transfection with a miRNA-320 agomir and then exposure to ionizing radiation with 4 Gy. The results were the mean of three independent experiments &#x00B1; standard deviation (&#x002A;&#x002A;P&#x003C;0.05). miRNA, microRNA; NC, negative control; si, small interfering RNA.</p></caption>
<graphic xlink:href="ol-12-06-4983-g02.jpg"/>
</fig>
<fig id="f4-ol-0-0-5340" position="float">
<label>Figure 4.</label>
<caption><p>Decrease in miRNA-320 induces the radioresistance of cervical cancer cells by targeting &#x03B2;-catenin expression. Determination of &#x03B2;-catenin as a target of miRNA-320 and effect of &#x03B2;-catenin on the radiosensitivity of cervical cancer cells. (A) The mRNA expression of &#x03B2;-catenin, c-MYC and cyclin D1 was decreased after transfection with miRNA-320 agomir. (B) Decreased expression of miRNA-320 facilitates the expression of &#x03B2;-catenin. (C) Increased expression of miRNA-320 inhibits the expression of &#x03B2;-catenin. (D) The protein level of &#x03B2;-catenin, c-MYC and cyclin D1 was decreased after transfection with miRNA-320 agomir. (E) siRNA-mediated inhibition of &#x03B2;-catenin in C33AR cells. (F) &#x03B2;-catenin inhibition rescues miRNA-320-mediated radioresistance of C33AR <italic>in vitro</italic>. C33AR cells were transfected with si-3 and si-NC, and the survival fractions were determined. The results shown (mean &#x00B1; standard deviation) are representative of three independent experiments (&#x002A;&#x002A;P&#x003C;0.05). miRNA, microRNA; NC, negative control; si/siRNA, small interfering RNA; mRNA, messenger RNA.</p></caption>
<graphic xlink:href="ol-12-06-4983-g03.jpg"/>
</fig>
</floats-group>
</article>
